# A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Source: https://onco.cc/trials/nct07149857/  
OnCo record `nct07149857` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ciltacabtagene autoleucel, Cyclophosphamide, Fludarabine in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel is a phase 2 interventional study registered as NCT07149857 by Janssen Research & Development, LLC, with 60 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-04-12. Interventions recorded: Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07149857
- Phase: 2
- Setting: A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07149857: https://clinicaltrials.gov/study/NCT07149857

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07149857.json